List view / Grid view
9 October 2013 | By Pfizer Inc.
“We are excited to see progress in our development program in psoriasis..."
3 October 2013 | By Pfizer Inc.
“The approval of DUAVEE, an important, novel and effective treatment, presents a new opportunity for women..."
25 September 2013 | By Pfizer
Long-term safety and efficacy data of XELJANZ up to five years will be presented at the American College Of Rheumatology 2013 annual meeting...
3 September 2013 | By Pfizer
Data show consistent results in reductions in stroke or systemic embolism, fewer major bleeding events, and reductions in all-cause death...
31 August 2013 | By Pfizer
Results presented at the ESC Congress 2013...
28 August 2013 | By Carbon Trust
ABPI collaborates with the Carbon Trust to help pharmaceutical companies quickly estimate the carbon footprint of tablet medicines distributed in blister packs...
In this RMMs & Environmental Monitoring In-Depth Focus: The rapid microbiological methods revolution; Controlling contamination in the pharmaceutical industry; Rapid Micro Methods Roundtable...
BioWa, Inc. and Lonza today announced that they have entered into research agreements with Pfizer Inc. allowing the use of the POTELLIGENT® CHOK1SV Cell Line in the research and development of multiple proprietary antibodies in Pfizer’s pipeline.
29 July 2013 | By Pfizer
Pfizer announces reduced advance market commitment price with a further reduction beginning in 2014...
16 July 2013 | By Pfizer Inc.
Pfizer provides update on XELJANZ® (tofacitinib citrate) for the treatment of rheumatoid arthritis...
11 July 2013 | By Bristol-Myers Squibb Company
FDA accepted for review a sNDA for Eliquis®
10 July 2013 | By Pfizer
Prevenar 13* received European approval...
20 June 2013 | By A*STAR Institute of Chemical and Engineering Sciences (ICES)
New programme aims to increase productivity with technology solutions for pharmaceutical and chemical sectors...
6 May 2013 | By Bristol-Myers Squibb Company
ARISTOTLE studied Eliquis vs. warfarin...
29 April 2013 | By Merck
Agreement to develop and commercialize Ertugliflozin, an investigational medicine for type 2 diabetes...
